Global Pharmaceutical Contract Development and Manufacturing Organization (CMO) Markets, Analysis and Forecast 2016-2021, 2021-2026F, 2031F

Dublin, April 11, 2022 (GLOBE NEWSWIRE) — The “Global Pharmaceutical Contract Development and Manufacturing Organization (CMO) Market Report 2022: By Type, By Research, By End-User” report has been added to from ResearchAndMarkets.com offer.

The global Pharmaceutical Contract Development and Manufacturing Organization (CMO) market is expected to grow from USD 114.36 billion in 2021 to USD 122.31 billion in 2022 at a compound annual growth rate (CAGR) of 7%.

The growth is primarily due to businesses resuming operations and adjusting to the new normal while recovering from the impact of COVID-19, which previously led to restrictive lockdown measures involving social distancing, remote work and the closure of business activities that have resulted in operational challenges.

The market is expected to reach $159.94 billion in 2026 with a CAGR of 6.9%.

The pharmaceutical contract development and manufacturing market includes sales of pharmaceutical contract development and manufacturing products and related services. Some pharmaceutical companies outsource the manufacturing of products under contract to focus on R&D, marketing and branding of their products. The pharmaceutical contract development and manufacturing market consists of manufacturing companies that manufacture drugs and other pharmaceutical products for other pharmaceutical companies on a contract basis.

The main types of pharmaceutical contract development and manufacturing (CMO) organization are active pharmaceutical ingredient (API) manufacturing, finished dosage formulation (FDF) development and manufacturing, secondary packaging. The manufacture of active pharmaceutical ingredients (APIs) includes the manufacture of the part of any drug that produces the desired effects. The different phases of research include preclinical phase, phase I, phase II, phase III, phase IV. The various end-use sectors include large pharmaceutical companies, generic pharmaceutical companies, small and medium pharmaceutical companies.

North America was the largest region in the pharmaceutical contract development and manufacturing market in 2021. The Middle East is expected to be the highest growth region during the forecast period. Regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The growth of the pharmaceutical contract development and manufacturing market is driven by the increase in demand for drugs across the globe. The high prevalence of diseases and the need for a longer lifespan have increased the demand for drugs pushing pharmaceutical companies to increase production of existing drugs and increase investment in their R&D to promote the development of new drugs.

This is driving pharma companies to collaborate with contract manufacturing organizations (CMOs) to reduce operational costs, thereby increasing the demand in the pharma contract development and manufacturing market.

The pharmaceutical contract development and manufacturing market is constrained by low capacity utilization of manufacturing facilities. Capacity utilization is calculated taking into account the full potential capacity of the production plant. The poor utilization of the capacity of the production plant is due to the inefficiency of the various sub-processes of the production line, which leads to low production.

The low production leads to low revenue generation for the production unit, affecting the overall contract pharma development and manufacturing market. Therefore, the underutilization of production plant capacity negatively affects the contract pharmaceutical development and manufacturing market.

Companies in the pharmaceutical contract development and manufacturing market invest in acquiring and forming alliances with other companies in the market.

Pharmaceutical contract development and manufacturing companies are following the trend of mergers and acquisitions in order to expand their reach in the global market to meet customer needs, increase production capacities while maintaining profitability and have access to the latest technologies and new services. High levels of merger and acquisition activity are driving the consolidation of contract service providers.

Main topics covered:

1. Summary

2. Characteristics of the Pharmaceutical Contract Development and Manufacturing Organization (CMO) Market

3. Pharmaceutical Contract Development and Manufacturing Organization (CMO) Market Trends and Strategies

4. Impact of COVID-19 on Contract Pharmaceutical Development and Manufacturing (CMO) Organization

5. Pharmaceutical Contract Development and Manufacturing Organization (CMO) Market Size and Growth
5.1. Global Historical Market for Pharmaceutical Contract Development and Manufacturing Organizations (CMOs), 2016-2021, in USD Billion
5.1.1. Market Drivers
5.1.2. Market Constraints
5.2. Global Pharmaceutical Contract Development and Manufacturing Organization (CMO) Market Forecast, 2021-2026F, 2031F, USD Billion
5.2.1. Market Drivers
5.2.2. Market Constraints

6. Pharmaceutical Contract Development and Manufacturing Organization (CMO) Market Segmentation
6.1. Global Pharmaceutical Contract Development and Manufacturing Organizations (CMOs) Market, Segmentation by Type, Historical & Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion

  • Manufacturing of Active Pharmaceutical Ingredients (API)
  • Development and manufacturing of finished dosage formulations (FDF)
  • Secondary packaging

6.2. Global Pharmaceutical Contract Development and Manufacturing Organizations (CMOs) Market, Segmentation by Research Phase, History and Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion

  • Preclinical
  • Phase I
  • Stage II
  • Phase III
  • Stage IV

6.3. Global Pharmaceutical Contract Development and Manufacturing Organizations (CMOs) Market, Segmentation by End User, Historical & Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion

  • Big Pharma
  • Generic pharmaceutical companies
  • Small and medium pharmaceutical companies

7. Regional and Country Analysis of the Pharmaceutical Contract Development and Manufacturing Organization (CMO) Market
7.1. Global Pharmaceutical Contract Development and Manufacturing Organizations (CMOs) Market, Split by Region, Historical & Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion
7.2. Global Pharmaceutical Contract Development and Manufacturing Organizations (CMOs) Market, Split by Country, Historical & Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion

Companies cited

  • Recipharm AB
  • Pfizer Inc.
  • Boehringer Ingelheim International GmbH
  • Aenova Group
  • famar
  • Jubilant Life Sciences Limited
  • Catalent Pharmaceutical Solutions
  • Limited chemicals
  • Dishman Pharmaceuticals
  • HAUPT Pharma AG
  • Kemwell Pvt. ltd.
  • Nipro Corp.
  • NextPharma
  • Royal DSM SA
  • Althea Technologies
  • Thermo Fisher Scientific Inc.
  • Lonza Group Ltd.
  • AbbVie Inc.
  • Consort Medical plc.
  • Almac Group
  • Siegfried Holding AG
  • Evonik Industries AG
  • Vetter Pharma International GMBH

For more information on this report, visit https://www.researchandmarkets.com/r/4lx7rd


CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

main logo